-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The pro-inflammatory cytokines interleukin 12 and tumor necrosis factor (TNF) play a role in the pathogenesis of psoriasis, while interleukin 17 and interleukin 23 are also involved in the pathogenesis of psoriasis, but the current TNF inhibitor is still silver Adalimumab is the main treatment method for scoria.
Recently, researchers compared the therapeutic effects of Bimekizumab and Adalimumab on moderate to severe plaque psoriasis.
Patients with moderate to severe plaque psoriasis were randomized to receive 320 mg Bimekizumab every 4 weeks for 56 weeks, 320 mg Bimekizumab every 4 weeks for 16 weeks, and then adjusted to 320 mg Bimekizumab every 8 weeks for 56 weeks or 40 mg Ada every 2 weeks Lumumab treatment lasted for 24 weeks, followed by 320 mg Bimekizumab every 4 weeks for 56 weeks.
478 patients participated in the study, 158 in the Bimekizumab treatment group every 4 weeks, 161 in the Bimekizumab treatment group and 159 in the adalimumab treatment group every 4 weeks and then 8 weeks.
86.
Studies believe that the therapeutic effect of Bimekizumab on moderate to severe plaque psoriasis is due to adalimumab, but the risk of diarrhea and infection is increased .
The effect of Bimekizumab in the treatment of moderate to severe plaque psoriasis is due to adalimumab, but the risk of diarrhea and infection is increased.
Richard B.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Leave a message here
